Arbutus Biopharma Corporation(ABUS)
$4.48▼-0.04 (-0.89%)
Arbutus Biopharma Corporation(ABUS)
NASDAQ
$4.48▼-0.04 (-0.89%)
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Revenue Growth | +58.92% | +255.11% | -53.51% | -65.98% | +128.21% |
| Gross Profit Growth | +127.09% | +255.11% | -53.51% | -65.98% | +0.00% |
| EBITDA Growth | -22.86% | +13.77% | -14.39% | +3.60% | +0.00% |
| Operating Income Growth | -27.19% | +10.97% | -19.32% | +2.28% | +0.00% |
| Net Income Growth | -19.61% | +8.91% | -4.89% | +4.02% | +0.00% |
| EPS Growth | +15.12% | +36.99% | +4.35% | +13.64% | +0.00% |
| EPS Diluted Growth | +15.12% | +36.99% | +4.35% | +13.64% | +0.00% |
| Weighted Average Shares Growth | +40.10% | +42.07% | +9.95% | +11.84% | +3.71% |
| Weighted Average Shares Diluted Growth | +40.10% | +42.07% | +9.95% | +11.84% | +3.21% |
| Dividends per Share Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -31.28% | +47.65% | -143.06% | +24.54% | +0.00% |
| Free Cash Flow Growth | -32.26% | +47.52% | -142.40% | +25.20% | +0.00% |
| 10Y Revenue Growth (per Share) | -92.82% | -74.97% | -89.20% | -95.22% | N/A |
| 5Y Revenue Growth (per Share) | +265.79% | +32.14% | +2.46% | -68.42% | N/A |
| 3Y Revenue Growth (per Share) | -3.05% | +145.53% | +19.89% | -67.85% | N/A |
| 10Y Operating CF Growth (per Share) | +4.33% | -109.67% | -17.46% | +39.31% | N/A |
| 5Y Operating CF Growth (per Share) | +41.74% | +73.64% | +57.82% | +71.91% | N/A |
| 3Y Operating CF Growth (per Share) | +48.23% | +81.17% | +23.66% | +45.03% | N/A |
| 10Y Net Income Growth (per Share) | +16.54% | -121.09% | +52.29% | +79.05% | N/A |
| 5Y Net Income Growth (per Share) | +90.09% | +70.18% | +57.49% | +86.01% | N/A |
| 3Y Net Income Growth (per Share) | +30.49% | +82.91% | +47.78% | +47.51% | N/A |
| 10Y Shareholders Equity Growth (per Share) | +246.75% | -69.58% | -83.50% | -87.14% | N/A |
| 5Y Shareholders Equity Growth (per Share) | -58.32% | -72.83% | -82.36% | -58.83% | N/A |
| 3Y Shareholders Equity Growth (per Share) | -55.95% | -28.84% | -52.49% | -67.11% | N/A |
| 10Y Dividend per Share Growth (per Share) | +0.00% | +0.00% | +0.00% | +0.00% | N/A |
| 5Y Dividend per Share Growth (per Share) | +0.00% | +0.00% | -100.00% | +0.00% | N/A |
| 3Y Dividend per Share Growth (per Share) | -37.38% | +0.00% | +0.00% | -100.00% | N/A |
| Receivables Growth | -31.48% | +50.39% | +31.36% | +35.64% | -27.48% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +49.17% | -4.43% | -26.11% | -8.79% | -28.16% |
| Book Value per Share Growth | +18.61% | -43.15% | -29.54% | -17.88% | -24.16% |
| Debt Growth | -16.09% | -33.62% | -30.52% | -85.22% | +224.90% |
| R&D Expense Growth | +32.76% | +28.86% | -12.69% | -26.68% | -53.29% |
| SG&A Expenses Growth | +15.43% | +4.07% | +26.02% | -1.63% | -38.47% |